Hanmi Pharm Co., Ltd. (128940)
KRX SM KRX SM Primary Summary
128940 Chart
Hanmi Pharm Co., Ltd. Dividends
| 128940 7 months ago | Other | ₩1,000 Per Share |
| 128940 27 Jun 2024 | Other | ₩250 Per Share |
| 128940 27 Dec 2023 | Other | ₩500 Per Share |
| 128940 28 Dec 2022 | Other | ₩490.2 Per Share |
| 128940 29 Dec 2021 | Other | ₩480.58 Per Share |
Hanmi Pharm Co., Ltd. Earnings
| 29 Oct 2025 (In 3 months) Date | | - Cons. EPS | - EPS |
| 24 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 30 Jul 2025 30 Jul 2025 Date | | 35.7 Cons. EPS | - EPS |
| 28 Jul 2025 Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 128940 7 months ago | Other | ₩1,000 Per Share |
| 128940 27 Jun 2024 | Other | ₩250 Per Share |
| 128940 27 Dec 2023 | Other | ₩500 Per Share |
| 128940 28 Dec 2022 | Other | ₩490.2 Per Share |
| 128940 29 Dec 2021 | Other | ₩480.58 Per Share |
| 29 Oct 2025 (In 3 months) Date | | - Cons. EPS | - EPS |
| 24 Oct 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 30 Jul 2025 30 Jul 2025 Date | | 35.7 Cons. EPS | - EPS |
| 28 Jul 2025 Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
Hanmi Pharm Co., Ltd. (128940) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Hanmi Pharm Co., Ltd. ever had a stock split?
Hanmi Pharm Co., Ltd. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Jae-Hyun Park CEO | KRX SM Exchange | KR7128940004 ISIN |
| KR Country | - Employees | - Last Dividend | 27 Dec 2023 Last Split | - IPO Date |
Overview
Hanmi Pharm. Co., Ltd. is an established biopharmaceutical entity dedicated to the development, production, and global distribution of pharmaceutical products. Since its inception in 1973, the company has been headquartered in Hwaseong-si, South Korea. With a solid footprint in key markets including South Korea, China, Japan, the United States, and other international territories, Hanmi Pharm has committed itself to addressing some of the most pressing health challenges. The company stands out for its concentrated efforts in tackling diseases that pose significant unmet medical demands, focusing on areas such as obesity, metabolism, oncology, and rare diseases. This strategic focus underscores Hanmi Pharm’s dedication to pioneering in territories where patient needs are yet to be fully met, leveraging both innovative research and development capabilities alongside a robust manufacturing infrastructure to deliver solutions that aim to improve patient outcomes across the globe.
Products and Services
Hanmi Pharm. Co., Ltd. specializes in a range of products and services designed to confront unmet medical needs, particularly in the fields of obesity, metabolism, oncology, and rare diseases. Below are key areas of focus:
- Obesity: Developing innovative treatments for obesity is a key endeavor for Hanmi Pharm, aiming to provide effective therapeutic options for this global health issue.
- Metabolism: The company invests in research and development of metabolic disorder treatments, targeting conditions that are often linked with obesity, such as diabetes and dyslipidemia. These efforts are pivotal in managing and potentially reversing the impacts of these widespread conditions.
- Oncology: In the field of oncology, Hanmi Pharm is dedicated to creating advanced cancer therapies. With a focus on precision medicine, the company seeks to offer targeted treatments that could significantly improve survival rates and quality of life for cancer patients.
- Rare Diseases: Recognizing the challenges in treating rare diseases, Hanmi Pharm is committed to the discovery and development of therapies for conditions that are often overlooked. This commitment highlights the company’s role in striving towards equity in healthcare by addressing the needs of patients with rare and less common diseases.
Contact Information
